Harrow, Inc. (HROW): A Bull Case Theory

We came crossed a bullish thesis connected Harrow, Inc. connected MVC Investing’s Substack by M. V. Cunha. In this article, we volition summarize the bulls’ thesis connected HROW. Harrow, Inc.'s stock was trading astatine $47.69 arsenic of February 16th. HROW’s trailing and guardant P/E were 9.64 and 44.25 respectively according to Yahoo Finance.

Tyler Olson/Shutterstock.com

Harrow, Inc., an eyecare pharmaceutical company, engages successful the discovery, development, and commercialization of ophthalmic pharmaceutical products. HROW delivered a beardown Q3, reporting grounds gross of $71.6M, up 45% YoY and 12% QoQ, with adjusted EBITDA of $22.7M (+158% YoY) and a 31.7% margin. Non-GAAP EPS of $0.35 exceeded expectations, reflecting unchangeable operating expenses and expanding operating leverage. Gross margins remained robust astatine 75% GAAP and 81% non-GAAP.

While 2025 gross guidance was somewhat lowered to $270–280M owed to a one-time $4–6M diminution in ImprimisRx revenue, absorption emphasized that the contented is resolved and underlying maturation trends stay intact. Harrow’s equilibrium expanse is strong, with $74M cash, $50M successful further liquidity, and refinancing that reduces involvement costs and extends maturities, supporting a blimpish leverage people of gross <3x and nett <2x EBITDA.

VEVYE continues to thrust growth, with Q3 gross up 21.5% QoQ to $22.6M and U.S. marketplace stock doubling to 10.5%, benefiting from expanded doc adoption, VAFA patient-access programs, and upcoming preferred PBM sum successful 2026. IHEEZO besides showed beardown momentum, increasing 20% QoQ and astir 70% YoY, supported by precocious reorder rates, wide GPO coverage, and a supportive reimbursement environment.

TRIESENCE is regaining traction pursuing its relaunch, with Q3 gross up 33% QoQ and the merchandise present entering the ocular inflammation marketplace with validated reimbursement. RSP remains a smaller, underperforming segment, while ImprimisRx provides dependable currency travel and operational stability.

Harrow’s pipeline is robust, with BYQLOVI launching successful Q1 2026, anti-VEGF biosimilars BYOOVIZ and OPUVIZ successful mid-2026/2027, and MELT-300 targeting sublingual sedation successful 2027–2028. Each inaugural enhances the halfway portfolio, complements existing products, and expands addressable markets.

With beardown execution, high-margin branded products, and a multi-year maturation runway, HROW is positioned for grounds 2025–2026 results and important semipermanent upside, offering investors a compelling risk/reward accidental with some near-term gross catalysts and long-dated optionality.